Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1992-03-03
1993-03-02
Evans, Joseph E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514 80, 514 91, 514 95, 514 97, 514 99, A61K 31185, A61K 31045, A61K 31095, A61K 3113
Patent
active
051909332
ABSTRACT:
Compounds of the formula I ##STR1## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, and their salts have GABA.sub.B -antagonistic properties and can be used as GABA.sub.B -antagonists. They are obtained when in a compound of formula II ##STR2## in which R, R.sup.1, R.sup.2 and R.sup.3 have their previous significances, Z represents --NH.sub.2 and R.sup.4 denotes a hydroxy-protective group R.sup.5 or, when R.sup.1 and R.sup.3 denote hydrogen and R.sup.2 denotes hydrogen or alkyl, denotes an alkali metal or ammonium ion R.sup.6, or Z represents a protected or latent amino group Z.sup.o and R.sup.4 denotes hydrogen or a hydroxy-protective group R.sup.5, any group R.sup.5 or R.sup.6 is replaced by hydrogen, and/or any group Z.sup.o is converted into --NH.sub.2.
REFERENCES:
patent: 2535175 (1950-12-01), Tawney
patent: 3184496 (1965-05-01), Baranavckas
patent: 3374288 (1968-03-01), Lange
patent: 3385822 (1968-03-01), Brown
patent: 3493639 (1970-02-01), Tavs
patent: 3637763 (1972-01-01), Firestone
patent: 3784590 (1974-01-01), Firestone
patent: 3812221 (1974-05-01), Braden
patent: 3970586 (1976-07-01), Schliebs
patent: 4064163 (1977-12-01), Drach
patent: 4322375 (1982-03-01), Maier
patent: 4390690 (1983-06-01), DiGiacomo
patent: 4399287 (1983-08-01), Baillie
patent: 4466913 (1984-08-01), Tsuruoka
patent: 4536355 (1985-08-01), Lee
patent: 4618358 (1986-10-01), Maier
patent: 4656298 (1987-04-01), Dingwall et al.
patent: 4657899 (1987-04-01), Rzeszotarski et al.
patent: 4740322 (1988-04-01), Thottathil
patent: 4772738 (1988-09-01), Dingwall
patent: 4908465 (1990-03-01), Dingwall
patent: 5004826 (1991-04-01), Dingwall
patent: 5013863 (1991-05-01), Baylis
patent: 5051524 (1991-09-01), Baylis
Neurology 41 (Supp. 1) 151, Abs. 131S (1991).
Annual Meeting of the Society for Neuroscience New Orleans, Nov. 10-15, 1991.
Aust. J. Chem 33, (1980) pp. 287-294.
Br. J. Pharm 101, 949 (1990).
Chem Abs. 57, 5946 (1962).
Chem Abs 97, 92585v (1982).
J. Med Chem 27, 654 (1984).
J. Pharma and Experimental Ther 235 (1) (1985).
Phosporous and Sulfur 18, 353 (1983).
Baylis Eric K.
Bittiger Helmut
Frostl Wolfgang
Hall Roger G.
Maier Ludwig
Ciba-Geigy Corporation
Evans Joseph E.
Fishman Irving M.
Kaiser Karen G.
LandOfFree
Substituted propane-phosphinic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted propane-phosphinic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted propane-phosphinic acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-126637